Pulmonary arterial hypertension
MONDO:0015924Pulmonary arterial hypertension (PAH) is a group of diseases characterized by mean pulmonary artery pressure >20 mmHg and elevated pulmonary arterial resistance leading to right heart failure. PAH is progressive and potentially fatal. PAH may be idiopathic and/ or familial, have overt features of venous/capillary involvement (pulmonary veno-occlusive disease, PVOD/pulmonary capillary hemangiomatosis, PCH), induced by drug or toxin (drug-or toxin-induced PAH), or associated with other diseases like congenital heart disease, connective tissue disease, HIV, schistosomiasis, portal hypertension (PAH associated with other disease).
Also known as: PAH, pulmonary arterial hypertension, PAH with overt features of venous/capillaries involvement, PVOD/PCH, PPH, idiopathic pulmonary hypertension
219 clinical trials for this condition and its sub-types, 202 tagged with Pulmonary arterial hypertension itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pulmonary arterial hypertension
-
Heritable pulmonary arterial hypertension 10 trials · 11 incl. sub-types
7 sub-types
- Pulmonary hypertension, primary, 2 1 trial
- Pulmonary hypertension, primary, 3 1 trial
- Pulmonary hypertension, primary, 4 1 trial
- Pulmonary hypertension, primary, 1 0 trials
- Pulmonary hypertension, primary, 5 0 trials
- Pulmonary hypertension, primary, 6 0 trials
- Pulmonary hypertension, primary, 7 0 trials
-
Eisenmenger syndrome 5 trials
-
New drug aims to help lungs and heart work better during exercise
Disease control Stopped earlyThis phase 3 trial tests whether ralinepag, an oral medication, can improve exercise capacity in people with pulmonary arterial hypertension (PAH) who have recently started PAH therapy. Participants take ralinepag or a placebo for 28 weeks, and their peak oxygen consumption durin…
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New biologic KER-012 shows promise for Hard-to-Treat lung condition
Disease control Stopped earlyThis phase 2 trial tested an experimental biologic called KER-012 in 113 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. Participants received either KER-012 or a placebo as a shot every 4 weeks, on top of their usual PAH…
Phase 2 • Sponsor: Keros Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Heart drug study halted early: limited data on right heart changes
Disease control Stopped earlyThis study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It planned to enroll 30 adults, but was terminated early, so results are limited. The goal was to use echocardiograms to…
Phase 4 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug sotatercept tested to slow PAH progression
Disease control Stopped earlyThis Phase 3 trial tested the drug sotatercept in 321 people newly diagnosed with intermediate- or high-risk pulmonary arterial hypertension (PAH). Participants received either sotatercept or a placebo added to their usual PAH therapy. The goal was to see if sotatercept could del…
Phase 3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
PAH drug LTP001 safety study ends early – limited data available
Disease control Stopped earlyThis study looked at the long-term safety of the drug LTP001 in people with pulmonary arterial hypertension (PAH), a serious lung condition. It was an open-label extension for patients who had completed a previous study. However, the study was terminated early, and no one reached…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Early-Stage lung blood pressure drug trial halted
Disease control Stopped earlyThis study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental PAH drug trial halted early
Disease control Stopped earlyThis study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the arteries in the lungs. The goal was to see if LTP001 could improve blood flow and exercise ability. However, the trial w…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New MRI technique could make heart procedures safer and faster
Knowledge-focused Stopped earlyThis study tests whether special low-energy MRI settings can make it safe to use guidewires during heart catheterization. Guidewires help position catheters but can heat up in standard MRI. Researchers will enroll 22 adults who need a right heart catheterization to see if this ap…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC